Condition
Prostate Specific Antigen
Total Trials
5
Recruiting
3
Active
3
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (3)
Trial Status
Recruiting3
Completed1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07516886Recruiting
Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy
NCT06862856Recruiting
Flotufolastat F 18 PET in Men With Very Low PSA Recurrence
NCT03704389Not ApplicableCompletedPrimary
Behavioral Economics Applications to Geriatrics Leveraging EHRs
NCT06748456Not ApplicableRecruiting
A Cluster Package Intervention to Promote an Evidence-based Use of PSA-tests in General Practice
NCT05009186Not ApplicableUnknown
Changing of Prostate Specific Antigen Value in Patients With Covid-19
Showing all 5 trials